Human Genome Epidemiology Literature Finder
|
Records 1 - 27 (of 27 Records) |
| Query Trace: Tuberculosis and CYP2B6[original query] |
|---|
| CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. Antimicrobial agents and chemotherapy 2009 Mar 53 (3): 863-8. Ramachandran Geetha, Hemanth Kumar A K, Rajasekaran Sikhamani, Kumar P, Ramesh K, Anitha S, Narendran G, Menon Pradeep, Gomathi C, Swaminathan Soum |
| Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. AIDS research and therapy 2010 7 (1): 8. Uttayamakul Sumonmal, Likanonsakul Sirirat, Manosuthi Weerawat, Wichukchinda Nuanjun, Kalambaheti Thareerat, Nakayama Emi E, Shioda Tatsuo, Khusmith Sris |
| Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy. AIDS (London, England) 2010 Dec . Kwara A, Lartey M, Sagoe KW, Court MH |
| Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clinical pharmacology and therapeutics 2011 Sep 90 (3): 406-13. Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel K-D, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli W E, Bertilsson L, Burhenne J, Aklillu |
| Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. Antimicrobial agents and chemotherapy 2012 Dec . Manosuthi W, Sukasem C, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S |
| Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia. The Journal of infectious diseases 2013 Aug . Bertrand J, Verstuyft C, Chou M, Borand L, Chea P, Nay KH, Blanc FX, Mentré F, Taburet AM |
| Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. BMC infectious diseases 2013 13 261. Mukonzo Jackson K, Okwera Alphonse, Nakasujja Neoline, Luzze Henry, Sebuwufu Deogratious, Ogwal-Okeng Jasper, Waako Paul, Gustafsson Lars L, Aklillu Ele |
| The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients. Antiviral research 2013 Dec . Bienvenu E, Swart M, Dandara C, Ashton M |
| Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4ß-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. The Journal of antimicrobial chemotherapy 2014 Dec 69 (12): 3311-9. Ngaimisi E, Minzi O, Mugusi S, Sasi P, Riedel K-D, Suda A, Ueda N, Bakari M, Janabi M, Mugusi F, Bertilsson L, Burhenne J, Aklillu E, Diczfalusy |
| CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1. Antimicrobial agents and chemotherapy 2014 58 (4): 2268-73. Manosuthi Weerawat, Sukasem Chonlaphat, Thongyen Supeda, Nilkamhang Samruay, Manosuthi Sukanya, Sungkanuparph Somnu |
| Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy. PloS one 2014 9 (2): e88497. Lee Kuan-Yeh, Lin Shu-Wen, Sun Hsin-Yun, Kuo Ching-Hua, Tsai Mao-Song, Wu Bing-Ru, Tang Sue-Yo, Liu Wen-Chun, Chang Sui-Yuan, Hung Chien-Chi |
| Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients. The Indian journal of medical research 2013 Dec 138 (6): 955-61. Ramachandran Geetha, Kumar A K Hemanth, Ponnuraja C, Ramesh K, Rajesh Lakshmi, Chandrasekharan C, Swaminathan Soum |
| Genetic variants of drug metabolizing enzymes and drug transporter (ABCB1) as possible biomarkers for adverse drug reactions in an HIV/AIDS cohort in Zimbabwe. Current HIV research 2013 Sep 11 (6): 481-90. Dhoro Milcah, Ngara Bernard, Kadzirange Gerald, Nhachi Charles, Masimirembwa Coll |
| Association of the CYP2B6 gene with anti-tuberculosis drug-induced hepatotoxicity in a Brazilian Amazon population. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2015 Apr 33 28-31. Fernandes Débora Christina Ricardo Oliveira, Santos Ney Pereira Carneiro, Moraes Milene Raiol, Braga Ana Cristina Oliveira, Silva Cleonardo Augusto, Ribeiro-dos-Santos Andrea, Santos Sidn |
| Efavirenz dosing: influence of drug metabolizing enzyme polymorphisms and concurrent tuberculosis treatment. Antiviral therapy 2015 20 (3): 297-306. Gengiah Tanuja N, Botha Julia H, Yende-Zuma Nonhlanhla, Naidoo Kogieleum, Abdool Karim Salim |
| CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population. Pharmacogenomics 2016 Apr . Mukonzo Jackson K, Bisaso Ronald K, Ogwal-Okeng Jasper, Gustafsson Lars L, Owen Joel S, Aklillu Ele |
| Association of CYP2B6 gene polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a Chinese population. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 2017 Apr . Wang Yu, Xiang Xi, Wu Shou-Quan, Chen Guo, Zhang Miao-Miao, Wang Ming-Gui, Wang Feng-Juan, Sandford Andrew J, He Jian-Qi |
| Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2018 Aug . Cerrone Maddalena, Wang Xinzhu, Neary Megan, Weaver Christine, Fedele Serge, Day-Weber Isaac, Owen Andrew, Hill Andrew, McClure Myra, Boffito Mar |
| Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin. European journal of clinical pharmacology 2018 7 74 (11): 1405-1415. Mugusi Sabina, Ngaimisi Eliford, Janabi Mohammed, Mugusi Ferdinand, Minzi Omary, Aris Eric, Bakari Muhammad, Bertilsson Leif, Burhenne Juergen, Sandstrom Eric, Aklillu Ele |
| Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype. Scientific reports 2018 Nov 8 (1): 16316. Kitabi Eliford Ngaimisi, Minzi Omary Mashiku Sylivester, Mugusi Sabina, Sasi Philip, Janabi Mohamed, Mugusi Ferdinand, Bertilsson Leif, Burhenne Jürgen, Aklillu Ele |
| Cytochrome P450 CYP2B6*6 distribution among Congolese individuals with HIV, Tuberculosis and Malaria infection. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2019 Feb . Peko Simon Marie, Gueye Nerly Shirère Gampio, Vouvoungui Christevy, Koukouikila-Koussounda Félix, Kobawila Simon Charles, Nderu David, Velavan Thirumalaisamy P, Ntoumi Franci |
| Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand. Clinical therapeutics 2020 May . Chaivichacharn Piyawat, Avihingsanon Anchalee, Manosuthi Weerawat, Ubolyam Sasiwimol, Tongkobpetch Siraprapa, Shotelersuk Vorasuk, Punyawudho Baral |
| Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis. International journal of environmental research and public health 2019 Dec 17 (1): . Yu Ya-Yen, Tsao Shih-Ming, Yang Wen-Ta, Huang Wei-Chang, Lin Ching-Hsiung, Chen Wei-Wen, Yang Shun-Fa, Chiou Hui-Ling, Huang Yi-W |
| Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis. Pharmacogenetics and genomics 2021 Aug . Haas David W, Mngqibisa Rosie, Francis Jose, McIlleron Helen, Robinson Jennifer A, Kendall Michelle A, Baker Paxton, Mawlana Sajeeda, Badal-Faesen Sharlaa, Angira Francis, Omoz-Oarhe Ayotunde, Samaneka Wadzanai P, Denti Paolo, Cohn Susan E, |
| Pharmacogenetic predictors of nevirapine pharmacokinetics in Ghanaian children living with HIV with or without TB coinfection. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 2021 4 92 104856. Langaee Taimour, Al-Shaer Mohammad H, Gong Yan, Lima Elizabeth, Antwi Sampson, Enimil Anthony, Dompreh Albert, Yang Hongmei, Alghamdi Wael A, Wiesner Lubbe, Peloquin Charles A, Kwara Awewu |
| Effects of rifampicin, CYP2B6 and ABCB1 polymorphisms on efavirenz plasma concentration in Chinese patients living with HIV and tuberculosis. International journal of STD & AIDS 2022 11 34 (1): 37-47. Zhang Li, Meng Xianmin, Dong Ping, Qi Tangkai, Liu Li, Wang B |
| Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis. Pharmacogenetics and genomics 2023 6 . Nana Agyemang, Kimberly K Scarsi, Paxton Baker, Laura M Smeaton, Anthony T Podany, Maxine Olefsky, Elizabeth Woolley, Elizabeth Barr, Michelle Pham, Sajeeda Mawlana, Khuanchai Supparatpinyo, Sivaporn Gatechompol, Emilia M Jalil, Luis Gadama, Sharlaa Badal-Faesen, Marije Van Schalkwyk, Cecelia Kayama, Pablo F Belaunzaran-Zamudio, Catherine Godfrey, Susan E Cohn, Rosie Mngqibisa, David W Haas, |
- Page last reviewed:Feb 1, 2024
- Content source: